417 related articles for article (PubMed ID: 33966624)
1. Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment.
Edupuganti VVSR; Tyndall JDATDA; Gamble AB
Recent Pat Anticancer Drug Discov; 2021; 16(4):479-497. PubMed ID: 33966624
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
3. Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
Pillow TH; Schutten M; Yu SF; Ohri R; Sadowsky J; Poon KA; Solis W; Zhong F; Del Rosario G; Go MAT; Lau J; Yee S; He J; Liu L; Ng C; Xu K; Leipold DD; Kamath AV; Zhang D; Masterson L; Gregson SJ; Howard PW; Fang F; Chen J; Gunzner-Toste J; Kozak KK; Spencer S; Polakis P; Polson AG; Flygare JA; Junutula JR
Mol Cancer Ther; 2017 May; 16(5):871-878. PubMed ID: 28223423
[TBL] [Abstract][Full Text] [Related]
4. Perspectives About Self-Immolative Drug Delivery Systems.
Gonzaga RV; do Nascimento LA; Santos SS; Machado Sanches BA; Giarolla J; Ferreira EI
J Pharm Sci; 2020 Nov; 109(11):3262-3281. PubMed ID: 32860799
[TBL] [Abstract][Full Text] [Related]
5.
Lee VEY; Lim ZC; Chew SL; Ang WH
Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
[TBL] [Abstract][Full Text] [Related]
7. Antibody Drug Conjugates for Cancer Therapy.
Polakis P
Pharmacol Rev; 2016 Jan; 68(1):3-19. PubMed ID: 26589413
[TBL] [Abstract][Full Text] [Related]
8. Design of self-immolative linkers for tumour-activated prodrug therapy.
Tranoy-Opalinski I; Fernandes A; Thomas M; Gesson JP; Papot S
Anticancer Agents Med Chem; 2008 Aug; 8(6):618-37. PubMed ID: 18690826
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE; Cotreau M; Han TH; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
[TBL] [Abstract][Full Text] [Related]
10. Prodrugs for targeted cancer therapy.
Souza C; Pellosi DS; Tedesco AC
Expert Rev Anticancer Ther; 2019 Jun; 19(6):483-502. PubMed ID: 31055990
[No Abstract] [Full Text] [Related]
11. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy.
Joubert N; Denevault-Sabourin C; Bryden F; Viaud-Massuard MC
Eur J Med Chem; 2017 Dec; 142():393-415. PubMed ID: 28911823
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy.
Hasan M; Alam S; Poddar SK
Curr Clin Pharmacol; 2018; 13(4):236-251. PubMed ID: 30073930
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
Malik P; Phipps C; Edginton A; Blay J
Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates: Current status and future perspectives.
Gébleux R; Casi G
Pharmacol Ther; 2016 Nov; 167():48-59. PubMed ID: 27492898
[TBL] [Abstract][Full Text] [Related]
15. Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
Kubizek F; Eggenreich B; Spadiut O
Protein Pept Lett; 2017; 24(8):686-695. PubMed ID: 28741467
[TBL] [Abstract][Full Text] [Related]
16. Azobenzene-Based Linker Strategy for Selective Activation of Antibody-Drug Conjugates.
Xiao D; Liu L; Xie F; Dong J; Wang Y; Xu X; Zhong W; Deng H; Zhou X; Li S
Angew Chem Int Ed Engl; 2024 Apr; 63(16):e202310318. PubMed ID: 38369681
[TBL] [Abstract][Full Text] [Related]
17. Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.
Xu S
Pharm Res; 2015 Nov; 32(11):3577-83. PubMed ID: 26108878
[TBL] [Abstract][Full Text] [Related]
18. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.
Weng W; Meng T; Zhao Q; Shen Y; Fu G; Shi J; Zhang Y; Wang Z; Wang M; Pan R; Ma L; Chen C; Wang L; Zhou B; Zhang H; Pu J; Zhang J; Hu YP; Hua G; Qian Y; Liu SH; Hu W; Meng X
Cancer Discov; 2023 Apr; 13(4):950-973. PubMed ID: 36693125
[TBL] [Abstract][Full Text] [Related]
20. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
Lu J; Jiang F; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
